Injunction granted in HKIAC dispute over leukaemia treatment
A Nasdaq-listed biopharma company says it has won emergency relief at the Hong Kong International Arbitration Centre requiring its Chinese partner to halt the commercialisation of a cell therapy treatment for leukaemia.
To read more
Subscribe to Global Arbitration Review
Register for limited access
Register for free to receive GAR’s daily briefing and access to GAR 100.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now